Sülfasalazine Bağlı Psikotik Özellikli Majör Depresif Bozukluk
Küçük Resim Yok
Tarih
2018
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Erişim Hakkı
info:eu-repo/semantics/openAccess
Özet
Ankilozan spondilit (AS); nedeni bilinmeyen, esasen omurgayı olmak üzere diğer eklemleri de etkileyebilen kronik inflamatuar bir hastalıktır. AS, spondiloartropatilerin prototipi olup dünya nüfusunun % 0,9'unu etkilemektedir. Sülfasalazin, AS tedavisinde kullanılan hastalık modifiye edici antiromatizmal ilaçlardan biridir. Sülfasalazinin; mani, depresyon ve psikoz gibi ciddi psikiyatrik problemler de dahil olmak üzere merkezi sinir sistemi üzerinde olumsuz etkilere yol açtığına dair olgular nadir olarak bildirilmiştir. Bu yazıda, psikotik özellikli majör depresif bozukluk nedeniyle başvuran bir erkek hasta sunulmaktadır. Hastada ciddi psikiyatrik belirtiler gelişirken, AS için günde 1000 mg sülfasalazin alıyordu. Romatoloji bölümüne konsulte edilen hastanın, sülfasalazinin psikiyatrik semptomların nedeni olabileceğinden şüphelenildiği için, sulfasalazin tedavisi kesildi. Şikayetler, psikiyatrik tedavinin başlangıcından 1 ay sonra tamamen geriledi.
Ankylosing spondylitis (AS) is a chronic inflammatory disease of unknown cause and affects mainly the spine, but can also affect other joints. AS is the prototype of spondyloarthropathies that affects 0,9% of the world population. Sulfasalazine is a disease-modifying antirheumatic drug used in the treatment of AS. Sulfasalazine may cause central nervous system adverse effects such as serious psychiatric problems including mania, depression, and psychosis, and these symptoms have been reported to occur only infrequently. This present case reports a male patient who presented due to major depressive disorder with psychotic features. He had been receiving 1000 mg/day sulfasalazine for AS while he developed serious psychiatric symptoms. The patient was stopped being given sulfasalazine after consulting rheumatology, as it was suspected sulfasalazine might have been the cause of his psychiatric symptoms. Complaints were fully resolved 4 months after the beginning of the 1 year psychiatric treatment.
Ankylosing spondylitis (AS) is a chronic inflammatory disease of unknown cause and affects mainly the spine, but can also affect other joints. AS is the prototype of spondyloarthropathies that affects 0,9% of the world population. Sulfasalazine is a disease-modifying antirheumatic drug used in the treatment of AS. Sulfasalazine may cause central nervous system adverse effects such as serious psychiatric problems including mania, depression, and psychosis, and these symptoms have been reported to occur only infrequently. This present case reports a male patient who presented due to major depressive disorder with psychotic features. He had been receiving 1000 mg/day sulfasalazine for AS while he developed serious psychiatric symptoms. The patient was stopped being given sulfasalazine after consulting rheumatology, as it was suspected sulfasalazine might have been the cause of his psychiatric symptoms. Complaints were fully resolved 4 months after the beginning of the 1 year psychiatric treatment.
Açıklama
Anahtar Kelimeler
Cerrahi
Kaynak
Süleyman Demirel Üniversitesi Tıp Fakültesi Dergisi
WoS Q Değeri
Scopus Q Değeri
Cilt
25
Sayı
1
